Mesenchymal Stem Cells-Derived Exosomes is under clinical development by Cellular Biomedicine Group and currently in Phase II for Acute Respiratory Distress Syndrome. According to GlobalData, Phase II drugs for Acute Respiratory Distress Syndrome have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Mesenchymal Stem Cells-Derived Exosomes’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mesenchymal Stem Cells-Derived Exosomes overview
The drug candidate is under development for the treatment of moderate to severe acute respiratory distress syndrome, pneumonia caused by beta-coronavirus(SARS-CoV-2 or Covid-19) and dementia due to Alzheimer's disease. It is administered through inhalation route as an aerosol and as intravenous bolus. The drug candidate comprises of exosomes derived from allogenic adipose mesenchymal stem cells(MSCs-Exo).
For a complete picture of Mesenchymal Stem Cells-Derived Exosomes’s drug-specific PTSR and LoA scores, buy the report here.